Lymphoma Clinical Trials

Showing 681-700 of 1,633 trials

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

NCT05715606

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

Anhui Provincial Hospital18 participantsStarted Feb 2023

Hefei, Anhui, China

TERMINATEDPHASE2

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.

Lymphoma

Eastern Cooperative Oncology Group26 participantsStarted Aug 2007

Stanford, California, United States • Gainesville, Florida, United States • Jacksonville, Florida, United States +65 more locations

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Related Searches

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm Study

CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Expanded Access Program for Epcoritamab

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

CAR T Cell Therapy Related Cardiovascular Outcomes

Frontline of ASCT in High-risk DLBCL

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Safety Study of SEA-CD40 in Cancer Patients

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas